Cargando…
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial
BACKGROUND: Soft-tissue sarcomas (STS) in the extremities and trunk treated with standard-of-care preoperative external beam radiation therapy (EBRT) followed by surgical resection are associated with local and distant relapses. In preclinical studies, oncolytic virotherapy in sarcoma has demonstrat...
Autores principales: | Monga, Varun, Miller, Benjamin J, Tanas, Munir, Boukhar, Sarag, Allen, Bryan, Anderson, Carryn, Stephens, Laura, Hartwig, Stacey, Varga, Steven, Houtman, Jon, Wang, Lei, Zhang, Weizhou, Jaber, Omar, Thomason, Jon, Kuehn, David, Rajput, Maheen, Metz, Catherine, Zamba, K.D., Mott, Sarah, Abanonu, Chinemerem, Bhatia, Sudershan, Milhem, Mohammed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327848/ https://www.ncbi.nlm.nih.gov/pubmed/34330766 http://dx.doi.org/10.1136/jitc-2021-003119 |
Ejemplares similares
-
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021) -
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
por: Malvehy, Josep, et al.
Publicado: (2021) -
Intratumoral administration of CD1c (BDCA-1)(+) and CD141 (BDCA-3)(+) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
por: Schwarze, Julia Katharina, et al.
Publicado: (2022) -
Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
por: Swami, Umang, et al.
Publicado: (2019) -
Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018)